Drug Database
NI

nifedipine once daily (Unipene / Unipene XL / nifedipine, Triglas)

✓ Approved

Actavis · CACNA1C · 小分子

什么是 nifedipine once daily?

nifedipine once daily 是一种小分子,由Actavis研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Unipene, Unipene XL, nifedipine, Triglas
公司Actavis
药物类别小分子
分子靶点CACNA1C
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

nifedipine once daily 作用于 1 个分子靶点:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

nifedipine once daily 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedGlobal advances in integrative medicine and health2026-11-18

Evaluation of a Single Daily Dose of a Plant-Based Nutraceutical for Subclinical Changes in Liver Function in Healthy Adults: An Exploratory, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

D'Adamo Christopher R CR, Shah Saumin S, Dudhatra Nimish N, Patel Ghanashyam G

There is growing interest in supplements to support liver health. Previous clinical trials evaluating an organic liquid nutraceutical formulation containing a mix of turmeric, dandelion, ginger, and milk thistle demonstrated favorable modulation of liver function markers in both healthy adults and those with fatty liver disease. To evaluate the efficacy and safety of once daily supplementation of the liquid nutraceutical formulation on liver function in healthy adults. This randomized, double-blind, placebo-controlled, clinical study enrolled healthy adults (18 to 60 years) with normal liver function. Participants were randomized 1:1 to receive the test product or placebo once daily, provided as a 60 mL oral solution, for 90 days. The primary outcome was change in liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT]) from baseline to end of treatment and was compared between study arms utilizing analysis of covariance. 108 participants enrolled and were randomized (n=54 per group). The mean ± standard deviation change from baseline for the test product and placebo groups were -3.5 ± 4.3 IU/L and +2.5 ± 7.4 IU/L for ALT (p <0.001), -2.7 ± 4.1 IU/L and +2.5 ±7.4 IU/L for AST (p <0.001), -7.6 ± 17.1 U/L and +6.2 ± 16.7 U/L for ALP (p <0.001), and -6.1 ± 10.9 IU/mL and +4.0 ± 6.8 IU/mL for GGT (p <0.001). No adverse events were reported. Once daily supplementation with this liquid nutraceutical formulation was safe, feasible, and significantly improved markers of liver function in healthy adults. The lower levels of ALT, AST, and GGT within the normal range noted in this study may be associated with clinical benefit. The findings at this single daily dose may support compliance among those aiming to support their liver health.

PMID 43048154
阅读全文 →
PubMedDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2026-11-18

Topical Minoxidil for Female Pattern Hair Loss: Clinical Outcomes in Postmenopausal Women.

Waide Ramond J RJ, Liu Hsiao-Pin HP, Patel Shah Asha A, Kamrani Payvand P et al.

Female pattern hair loss (FPHL) affects up to 50% of women and becomes increasingly prevalent after menopause. Declining estrogen levels, altered hormonal balance, and follicular miniaturization contribute to disease progression, which can substantially impair quality of life (QoL). The aim of this study was to review the pathophysiology and psychosocial impact of FPHL, discuss patient counseling and treatment expectations, and evaluate the benefits of topical minoxidil in postmenopausal women. Published evidence on FPHL pathophysiology, psychosocial outcomes, treatment barriers, and minoxidil efficacy and tolerability was searched for online using Google and via PubMed. Publications were reviewed for relevance based on the objectives as listed above before being selected for inclusion in our narrative. Findings from a post hoc subgroup analysis of postmenopausal women in a phase III clinical trial of once-daily 5% minoxidil topical foam (MTF) were also assessed. FPHL is influenced by genetic susceptibility, aging, and menopausal hormonal changes. Hair loss is associated with reduced self-esteem, social withdrawal, anxiety, and impaired QoL. Delayed treatment initiation is common. In a phase III study, 5% MTF significantly increased hair count versus vehicle at 24 weeks. Post hoc analyses demonstrated significant hair regrowth in postmenopausal women with both early and advanced hair loss. Once-daily 5% MTF is effective in postmenopausal women regardless of disease severity. Early recognition, patient education, individualized treatment selection, and psychosocial support are essential for optimal outcomes.

PMID 43049345
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Low-Dose Oral Versus Topical Minoxidil in Androgenetic Alopecia: A Randomized, Double-Blind, Double-Dummy Controlled Trial.

Chaudhry Muhammad Asad Ejaz MAE, Muneeb Bushra B, Aamir Safoora S, Saeed Zoha Arif ZA et al.

Androgenetic alopecia (AGA) is a prevalent, progressive condition with significant psychosocial impact. Current pharmacological modalities like topical minoxidil and finasteride have limitations. Low-dose oral minoxidil has surfaced as a valid off-label solution, with the practical advantage of once-daily dosing. To evaluate the efficacy and safety of topical and oral minoxidil in AGA. In this double-blind, double-dummy randomized controlled trial, 100 patients aged 18-50 years with AGA were randomized to receive either twice-daily topical minoxidil (5% in males, 2% in females) plus a placebo tablet, or once-daily oral minoxidil (2.5 mg in males, 1.25 mg in females) plus a placebo spray for 6 months. The primary outcome was the proportion of patients achieving ≥ +1 improvement in a validated 7-point global photographic scale. Secondary outcomes included patient satisfaction and adverse effects. Data were analyzed using SPSS v26 with p ≤ 0.05 as significant. Ninety patients completed 24 weeks of follow-up. Photographic assessment demonstrated that mild-to-excellent improvement (≥ +1) occurred in both the oral (67%) and topical minoxidil (73%) groups (p = 0.652). Patient-reported satisfaction was high in both groups (topical: 70.5%; oral: 80.4%, p = 0.332), with a non-significant trend favoring oral minoxidil at the moderate satisfaction threshold (58.7% vs. 38.6%, p = 0.057). Median improvement scores were comparable between groups for both clinician assessment and patient-reported outcomes. Hypertrichosis was significantly more frequent with oral minoxidil (30% vs. 9%, p = 0.011), whereas contact dermatitis was exclusive to topical minoxidil (11% vs. 0%, p = 0.025). No serious adverse events were observed. Both topical and low-dose oral minoxidil demonstrated clinically meaningful improvement in androgenetic alopecia. Despite oral therapy exhibiting a trend toward higher patient satisfaction, this study was not powered to establish non-inferiority or equivalence. The dermatologist-assessed outcomes indicated no significant intergroup differences. Low-dose oral minoxidil may be considered a practical alternative in selected patients, particularly where adherence to topical therapy is limited. ClinicalTrials.gov: NCT07273799.

PMID 43047224
阅读全文 →
PubMedFrontiers in medicine2026-11-18

Case Report: Manual review of a gray-zone multiplex PCR targeted sequencing signal in clinically diagnosed pulmonary cryptococcosis.

Xiang Yuan Y, Liu Shui-Yi SY, Cao Guijuan G, Wu Tang-Wei TW et al.

Pulmonary cryptococcosis may be difficult to diagnose when clinical manifestations are nonspecific and conventional microbiological tests are negative. Multiplex PCR-based targeted next-generation sequencing (mp-tNGS) can provide rapid pathogen evidence, but weak fungal signals require careful interpretation. A 47-year-old apparently immunocompetent woman was admitted with persistent bilateral pulmonary lesions after empirical antibacterial treatment. Bacterial and fungal cultures, fungal smears, acid-fast staining, and Mycobacterium tuberculosis nucleic acid testing were all negative for both sputum and bronchoalveolar lavage fluid (BALF) specimens. BALF mp-tNGS yielded low-confidence Cryptococcus spp. signals. The putative C. neoformans assignment had 1,414 normalized reads and one positive primer pair among six; the putative C. gattii assignment had 78 normalized reads and two positive primer pairs among three. Neither established species identity. Manual review considered run quality and negative controls alongside positive serum cryptococcal antigen and supportive India ink microscopy. The patient was managed as having clinically diagnosed pulmonary cryptococcosis. HIV testing was negative, and the CD4T-cell count was 600 cells/µL. Blood culture was negative. She had no headache, vomiting, or focal neurological signs; however, no CSF CrAg, culture, India ink microscopy, or mp-tNGS was performed. She received intravenous fluconazole 400 mg once daily after an 800-mg loading dose from 18 to 23 December 2025, followed by oral fluconazole 600 mg once daily. Symptoms improved; imaging showed early progression followed by partial improvement, with persistent cavitary changes. Low-level fungal mp-tNGS signals warrant multidisciplinary review integrating technical quality, specimen type, antigen testing, microscopy, culture, and clinical findings. Species-specific confirmation should be pursued when feasible. This proposed BALF review framework requires prospective validation and should not be transferred directly to CSF or other specimens.

PMID 43047450
阅读全文 →
PubMedJCEM case reports2026-11-18

New-onset depersonalization-derealization syndrome following semaglutide therapy.

Prasad Sai S, Sharma Anukriti A, Sharma Anubhooti A, Parmar Vidhi V et al.

Semaglutide, a glucagon-like peptide-1 receptor agonist prescribed for type 2 diabetes and obesity, acts on central neuropsychiatric pathways beyond its metabolic effects, yet dissociative adverse effects have rarely been reported. We describe a 42-year-old woman with no psychiatric history who developed recurrent, distressing episodes of depersonalization and derealization approximately 7 days after her second 0.5 mg weekly dose of semaglutide prescribed for obesity. The episodes progressed from once daily to 3 to 4 times daily over 10 days, with insight and reality testing preserved throughout. Metabolic, neurological, toxicological, and psychiatric evaluations, including brain imaging, electroencephalography, and laboratory studies, excluded alternative causes. She fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for depersonalization-derealization disorder, and the Naranjo Adverse Drug Reaction Probability Scale score of 6 indicated a probable causal relationship. Semaglutide was discontinued without psychotropic medication, and symptoms resolved completely within 4 weeks, with sustained remission at 3 months. This case suggests that depersonalization-derealization is an underrecognized, reversible neuropsychiatric adverse effect of semaglutide and underscores the need for clinician awareness and patient counseling during therapy.

PMID 43048071
阅读全文 →
PubMedCureus2026-11-18

Cutaneous Lupus Erythematosus/Lichen Planus Overlap Syndrome With Vitiligo-Like Depigmentation: A Case Report.

Alkandari Danah D, Ashkanani Hasan Kh A H A HKAHA, Mayouf Hawraa H, Alajmi Ali A et al.

Cutaneous lupus erythematosus/lichen planus (CLE/LP) overlap syndrome is an uncommon interface dermatosis with features of both disorders. We describe a 60-year-old woman who initially developed pruritic, erythematous, scaly lesions on the dorsal hands, and facial erythema. The initial eruption resolved spontaneously within two months, without treatment, followed by persistent depigmented and erythematous patches at the previously affected sites. Wood's lamp examination accentuated the depigmentation. Histopathology of a depigmented dorsal-hand patch showed interface dermatitis with basal vacuolar alteration and a bandlike lymphocytic infiltrate. Melan-A staining on the same specimen demonstrated melanocyte loss. Direct immunofluorescence of perilesional skin showed immunoglobulin deposition at the dermoepidermal junction and shaggy fibrinogen staining. The findings supported CLE/LP overlap syndrome with subsequent vitiligo-like depigmentation. Hydroxychloroquine 200 mg twice daily and once-daily topical ruxolitinib were initiated; mild repigmentation at the oral commissure was documented clinically and with Wood's lamp examination at one month. Distinguishing coexisting vitiligo from post-inflammatory melanocyte loss remains challenging, and the temporal association does not establish causality.

PMID 43048709
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nifedipine once daily